SPK 843

Drug Profile

SPK 843

Alternative Names: IB 643; SPA S 752; SPA S 753; SPA S 843

Latest Information Update: 19 Jan 2011

Price : $50

At a glance

  • Originator SPA
  • Developer Kaken Pharmaceutical; SPA
  • Class Antifungals
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Mycoses

Most Recent Events

  • 19 Jan 2011 No development reported - Phase-II for Mycoses in Japan (IV)
  • 28 May 2008 Discontinued - Preclinical for Mycoses in Italy (IV)
  • 28 May 2008 Pharmacodynamics data from preclinical trials in Mycoses released by Kaken Pharmaceutical Co. ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top